RAPT Therapeutics
RAPT
RAPT was delisted on the 2nd of March, 2026.
121 hedge funds and large institutions have $287M invested in RAPT Therapeutics in 2024 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 34 increasing their positions, 28 reducing their positions, and 24 closing their positions.
63% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 24
21% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 28
12% more funds holding
Funds holding: 108 → 121 (+13)
1.23% less ownership
Funds ownership: 12.71% → 11.48% (-1.2%)
17% less call options, than puts
Call options by funds: $9.91M | Put options by funds: $12M
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
67% less capital invested
Capital invested by funds: $869M → $287M (-$582M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$23.9M |
| 2 |
Morgan Stanley
New York
|
+$14.9M |
| 3 |
KCM
Kingdon Capital Management
New York
|
+$9.28M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.59M |
| 5 |
ABG
Ally Bridge Group
New York
|
+$7.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$44.6M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$31.8M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$27.3M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$24.1M |
| 5 |
SC
Samlyn Capital
New York
|
-$17.7M |
RAPT Hedge Fund Activity: Q1 2024 in Review
121 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in RAPT Therapeutics (RAPT) for Q1 2024, worth a combined $287M — down 67% from $869M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new RAPT positions and 24 closed out — a net gain of 15 holders — while 34 added to existing stakes and 28 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $23.9M. The largest seller was Deep Track Capital, exiting entirely with an estimated $44.6M sold.
- 121 institutional investors held RAPT Therapeutics (RAPT) as of Q1 2024, up from 108 in Q4 2023.
- Funds reported $287M of RAPT Therapeutics stock for Q1 2024, down 67% quarter-over-quarter.
- 39 funds opened new RAPT Therapeutics positions in Q1 2024 and 24 closed out, a net change of +15 holders.
- The largest RAPT Therapeutics buyer in Q1 2024 was Fidelity Investments, an estimated $23.9M added.
- The largest RAPT Therapeutics seller in Q1 2024 was Deep Track Capital, an estimated $44.6M sold.
Based on aggregated 13F filings for Q1 2024.